# Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

> **NCT02296138** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 7903 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** olodaterol
- **DRUG:** tiotropium
- **DRUG:** tiotropium

## Key facts

- **NCT ID:** NCT02296138
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-13
- **Primary completion:** 2017-03-08
- **Final completion:** 2017-03-29
- **Target enrollment:** 7903 (ACTUAL)
- **Last updated:** 2018-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02296138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02296138, "Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02296138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*